Event

This session will discuss new information about the expanding technologies for ex vivo lung perfusion (EVLP) to improve donor lung quality, insights into prevention of primary graft dysfunction (PGD), and paradigm changes in our understanding of phenotypes and mechanisms of chronic lung allograft dysfunction (CLAD). There will be discussion of the rapidly growing use of EVLP, new mechanistic insights to PGD etiology and prevention, and the approach to phenotypes of CLAD, including restrictive CLAD, its diagnosis, radiographic and pathological correlates. The session will also address the impact of lung microbiome and pulmonary infections upon innate immunity and CLAD development.